Does NAC increase live birth rates in PCOS?

There is no reliable trial evidence either way. The only PCOS trial that directly reported a live-birth number was retracted in November 2025, and the three meta-analyses that followed it (2015, 2020, 2023) either leaned on that trial, found no significant pregnancy benefit, or didn't analyse live birth at all.

What's the difference between NAC's ovulation rate and its pregnancy rate in these trials?

Ovulation was confirmed by ultrasound follicle tracking. 'Pregnancy' in most trials meant a single serum beta-hCG blood test roughly two weeks later — an early biochemical signal, not a confirmed ongoing pregnancy or a birth.

Why was the 2010 NAC ovarian-drilling trial retracted?

PubMed lists a retraction notice for that trial, published in November 2025, roughly 15 years after the original study. The notice does not need to be interpreted here — the practical point is that a retracted trial should not be treated as evidence, and this was the only PCOS trial reporting a live-birth number directly.

Should I take NAC instead of letrozole or metformin to try to conceive?

The trial evidence doesn't support that trade. Metformin beat NAC head-to-head on ovulation in every trial that tested both, and letrozole has a large trial that followed women through to live birth — something no NAC trial has done.

Is NAC's ovulation evidence in PCOS still worth taking seriously?

The ovulation finding itself is reasonably consistent across six small trials. What isn't supported is extending that finding to a live-birth claim, which is a different outcome that these trials did not measure.

Can NAC be combined with letrozole or clomiphene for PCOS?

Trials have tested both combinations and found more ovulation with NAC added than without it. Whether that translates to more live births has not been tested — bring the trial data to your prescriber rather than adding NAC on your own.

NAC for Ovulation in PCOS: What the Live-Birth Data Shows

A registered dietitian and clinician review is being arranged for this site. Until this article carries a named reviewer, treat it as a well-sourced summary of published guidance — not as a substitute for advice about your own case.

The short answer

Six small trials show NAC raises ovulation rates in PCOS, from roughly 7% to over 50% depending on the comparator. But only one trial ever measured live birth specifically — 67% versus 40% — and that trial was retracted in November 2025. No other NAC trial in PCOS has followed patients through to a live birth.

Does NAC Actually Help You Ovulate With PCOS?

Six randomized trials, run between 2005 and 2018, tested oral N-acetylcysteine (NAC) as an add-on to clomiphene or letrozole for inducing ovulation in PCOS, and every one of them found more ovulation on NAC than on the comparator it was tested against. That much is genuinely well established — the full evidence picture, including how NAC compares with inositol, sits on its own page and isn’t repeated here. What is not established, and what none of those six trials actually measured, is whether that extra ovulation turns into a baby. Ovulation and live birth are different outcomes, measured at different points in a treatment cycle, and conflating them is where most of the confidence about NAC and fertility comes from.

NAC is an amino-acid derivative sold over the counter, studied in PCOS as an antioxidant and mild insulin-sensitiser rather than as a hormone. The rationale researchers gave for testing it was straightforward: oxidative stress markers run higher in PCOS than in the general population, and if reducing that stress lowers the ovarian androgen output that blocks follicle development, more follicles should mature and ovulate. That mechanism is the reason NAC was tested at all — it says nothing about whether the resulting ovulation survives long enough to become a pregnancy that goes to term, which is a separate biological question the mechanism doesn’t answer either way.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), the name a 2026 global consensus of more than 50 organisations gave the same condition. Nothing about the trial evidence below changed with the rename; this article uses PCOS because that is still what most readers search.

What Do the NAC Ovulation Trials Actually Show?

Every trial in the table below measured ovulation directly — usually by ultrasound follicle tracking — and then reported something it called “pregnancy,” almost always a single blood test for β-hCG taken roughly two weeks after the treated cycle. None of them kept following the women who tested positive through to a delivery.

Table 1 — NAC ovulation trials in PCOS: what was measured, and what wasn't.

Trial	Population	Comparison	Ovulation rate	Followed to live birth?
Rizk 2005	150 women, clomiphene-resistant	NAC 1.2 g/day + clomiphene vs. placebo + clomiphene	49.3% vs. 1.3%	No — a single hCG-confirmed pregnancy rate (21.3% vs. 0%) was the endpoint
Badawy 2007	573 women enrolled, 470 completed both arms (cross-over)	Clomiphene alone, then clomiphene + NAC 1.2 g/day, same women, sequential cycles	17.9% vs. 52.1%	No — an 11.5% pregnancy rate was reported in the NAC cycle, nothing beyond it
Elnashar 2007	61 women, clomiphene-resistant, 6 weeks	NAC 1.8 g/day alone vs. metformin 1,500 mg/day alone	6.7% vs. 51.6%	No — the trial ended at 6 weeks; pregnancy was not a measured outcome
Salehpour 2012	180 women	NAC 1.2 g/day + clomiphene vs. placebo + clomiphene	Significantly higher (p=0.02)	No — “pregnancy” (p=0.04) meant a single serum β-hCG test 16 days after ovulation triggering
Abu Hashim 2010	192 women, clomiphene-resistant, 3 cycles	NAC + clomiphene vs. metformin + clomiphene	20.0% vs. 69.1%	No — pregnancy rate reported (5.3% vs. 22.7%); miscarriage was noted qualitatively, live birth never stated as a number
Mostajeran 2018	130 women	NAC 1.2 g/day + letrozole vs. placebo + letrozole	Significantly higher (p=0.045)	No — same single β-hCG protocol as Salehpour 2012

Read across that last column and the pattern is not subtle: six trials, six positive ovulation results, zero live-birth outcomes. That absence is not an oversight in this article — it is the actual state of the published evidence, and it is the finding.

What Happened When Someone Actually Tried to Measure Live Birth?

One trial in this literature did report a live-birth number directly, and it is now retracted. A 60-woman pilot study following unilateral ovarian drilling in clomiphene-resistant PCOS reported live birth in 67% of the NAC group versus 40% on placebo, alongside higher ovulation and pregnancy rates and a lower miscarriage rate — the only individual PCOS trial in this entire body of research that names a live-birth rate as a result. PubMed’s record for that retracted trial, dated November 2025, is public; a retracted trial is not evidence for anything, regardless of how good the number looked before the retraction.

That single retraction changes what three separate meta-analyses, spanning nearly a decade, are actually able to say about NAC and live birth.

Table 2 — three meta-analyses, and what each could actually say about live birth.

Source	Pooled women	What it reported about live birth
Thakker 2015 (8 pooled RCTs)	910	Abstract states NAC had higher odds of “having a live birth” than placebo — but the paper’s own conclusion calls for further trials “to examine clinical outcomes such as live birth rate in longer follow-up periods,” and the now-retracted pilot above is one of its eight source trials
Devi 2020 (15 pooled RCTs, PCOS and unexplained infertility combined)	2,330	Pooled pregnancy odds ratio 1.55 (95% CI 0.98–2.47) — not statistically significant. Live birth could not be pooled at all; the paper repeats, five years later, the same call for trials that examine “live birth rate”
Shahveghar Asl 2023 (18 pooled RCTs — the largest, most recent synthesis)	2,185	Pregnancy and live birth are not among the outcomes analysed at all. The review is limited to ovulation-related hormone markers (testosterone, FSH)

Why Doesn’t a Higher Ovulation Rate Guarantee a Live Birth?

Ovulation is a necessary step toward pregnancy, not a guarantee of one, and PCOS specifically adds distance between the two: not every ovulatory cycle is followed by conception, and not every conception is followed by a birth. Fertility research generally separates three checkpoints — ovulation, a biochemical pregnancy (a positive hCG test, which is what five of the six trials above actually measured), and a live birth — because the drop-off between each stage is real and each one requires its own evidence. A biochemical pregnancy can end in an early loss before it is ever confirmed clinically, and a confirmed clinical pregnancy can still end before term. How miscarriage risk factors into that gap is covered in full here, and it is exactly the reason a trial that only measures ovulation — or a single early hCG test — cannot answer the question most people actually want answered. The six ovulation trials above are honest about what they measured; the confusion comes from later summaries, including some meta-analyses, treating “more ovulation” and “more positive pregnancy tests” as though they already settled the live-birth question.

Does NAC’s Ovulation Effect Hold Up Against Letrozole or Metformin?

Not on the numbers available. Every trial that put NAC head-to-head against metformin found metformin ahead on ovulation — 51.6% versus 6.7% in one trial, 69.1% versus 20.0% in another — and the fuller metformin comparison, including who a prescriber weighs it for, is covered separately. Letrozole, the drug the 2023 international guideline now recommends first for ovulation induction in PCOS, has something NAC does not: a large, dedicated trial that followed women all the way to a live birth and reported a specific rate. The letrozole-versus-clomiphene comparison and that trial’s numbers are covered in depth here. NAC has never had that trial run for it. The Mostajeran 2018 study above added NAC to letrozole and found more ovulation and a better single-hCG result — a genuinely useful data point on its own — but it used the same short, early-pregnancy-test design as the rest of this literature, so it adds nothing to the live-birth question either.

Who This Evidence Will Not Help

If a live birth, specifically, is the outcome you care about, the trial evidence for NAC does not support choosing it over letrozole or metformin — both have stronger, more complete data behind them, and metformin outperforms NAC on ovulation in every direct comparison run. NAC’s evidence is also entirely about adjuvant use alongside clomiphene or letrozole in a monitored cycle; none of the six trials tested it as a standalone approach to infertility, and none of them enrolled women whose infertility involved a blocked fallopian tube or a male-factor sperm problem — both are causes NAC’s mechanism has no plausible way to address. No trial has isolated a PCOS phenotype that responds better to NAC, so there is no evidence-based way to predict who among the ovulation responders would also be a live-birth responder, because that outcome has simply never been measured in a trial that wasn’t later withdrawn. And if you are choosing NAC because a product description or a summary elsewhere describes it as improving live-birth chances, that claim is not something this literature currently supports — it is, at best, an extrapolation from an ovulation finding, and at worst it is quietly carrying forward a number from the retracted trial above without saying so.

Common questions

Does NAC increase live birth rates in PCOS?
There is no reliable trial evidence either way. The only PCOS trial that directly reported a live-birth number was retracted in November 2025, and the three meta-analyses that followed it (2015, 2020, 2023) either leaned on that trial, found no significant pregnancy benefit, or didn't analyse live birth at all.
What's the difference between NAC's ovulation rate and its pregnancy rate in these trials?
Ovulation was confirmed by ultrasound follicle tracking. 'Pregnancy' in most trials meant a single serum beta-hCG blood test roughly two weeks later — an early biochemical signal, not a confirmed ongoing pregnancy or a birth.
Why was the 2010 NAC ovarian-drilling trial retracted?
PubMed lists a retraction notice for that trial, published in November 2025, roughly 15 years after the original study. The notice does not need to be interpreted here — the practical point is that a retracted trial should not be treated as evidence, and this was the only PCOS trial reporting a live-birth number directly.
Should I take NAC instead of letrozole or metformin to try to conceive?
The trial evidence doesn't support that trade. Metformin beat NAC head-to-head on ovulation in every trial that tested both, and letrozole has a large trial that followed women through to live birth — something no NAC trial has done.
Is NAC's ovulation evidence in PCOS still worth taking seriously?
The ovulation finding itself is reasonably consistent across six small trials. What isn't supported is extending that finding to a live-birth claim, which is a different outcome that these trials did not measure.
Can NAC be combined with letrozole or clomiphene for PCOS?
Trials have tested both combinations and found more ovulation with NAC added than without it. Whether that translates to more live births has not been tested — bring the trial data to your prescriber rather than adding NAC on your own.

Your Next Step

If you’re weighing NAC specifically for its effect on ovulation and cycle mechanics, the full evidence overview and the dosing and side-effect data actually used in these trials cover what is genuinely established. If a live birth is the outcome you’re planning around, bring this page’s tables to your prescriber alongside what actually confirms ovulation in PCOS and the letrozole-versus-clomiphene live-birth comparison — both rest on evidence this literature does not yet have for NAC. The honest summary is not that NAC does not work; it is that nobody has run the trial that would tell you whether it does, for the outcome that actually matters.